Clinical trials: Hepatic Cirrhosis
Cirrhosis
Influence of Shunt Occlusion on Organ Functions in Hyperammonemic Patients With Cirrhosis Having Porto-systemic Shunt.
The spontaneous Porto-systemic shunt is occluded by intervention procedures like Balloon Occluded Retrograde Transvenous Obliteration (BRTO), Plug-assisted Retrograde Transvenous Obliteration (PARTO) and shunt occlusion…
- Trial name
- NCT03293459
- Testing
- Shunt Occlusion, Standard Medical Treatment (SMT)
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Steatosis, Fibrosis, Liver
Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver fibrosis in patients with screening criteria of metabolic dysfunction-associated…
- Trial name
- NCT06102980
- Testing
- Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement, Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement, Vibration-controlled transient elastography (VCTE) attenuation measurement
- Where
- Ecuador
- Volunteers
- 30 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Liver Cirrhosis, Ascites Hepatic
Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
Large volume paracentesis with albumin administration is the standard of care for patients with refractory ascites complicating end-stage liver disease.
- Trial name
- NCT03202524
- Testing
- Fresh Frozen Plasma (FFP), Albumin
- Sponsor
- Montefiore Medical Center
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Ascites
Phase Ib of Recombinant Human Albumin Injection
A Randomized, Multicenter,Open-label, positive-controlled, Multi-dose Phase 1 Study to Evaluate the Safety, Tolerance,Efficacy, Pharmacokinetics and Immunogenicity of recombinant human albumin injection in Patients With Hepatic…
- Trial name
- NCT04701697
- Testing
- Recombinant Human Albumin Injection, HumanAlbumin
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Hospital of Jilin University
Portal Hypertension, Cirrhosis, Liver
The vPPG-detecting Software Guided Management of Cirrhotic Portal Hypertension
The aim of this study is to investigate the possibilities and effectiveness of managing cirrhotic portal hypertension using the non-invasive portal pressure gradient (PPG) detecting software.
- Trial name
- NCT04786782
- Testing
- PPG-detecting software, LSM and PLT count
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Changqing Yang
Cirrhosis, Diabetes Mellitus
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and…
- Conditions
- Cirrhosis, Diabetes Mellitus, Oncologic Disorders
- Trial name
- CIBERbBECHO (NCT05769868)
- Testing
- Esmolol Injection [Brevibloc]
- Where
- 6 sites in Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Primary Biliary Cholangitis, Primary Biliary Cirrhosis
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy.
- Conditions
- Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis
- Trial name
- PRONTO-PBC (NCT04604652)
- Testing
- HTD1801 (BUDCA)
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Liver Cirrhosis, Gastroesophageal Varices
Risk Prediction of Bleeding in Liver Cirrhosis by Combi-elastography
Through the parameters of liver stiffness and spleen stiffness obtained by combi-elastography technique, summarize and analyze the warning index of esophagogastric variceal bleeding in patients with cirrhosis, so as to provide a…
- Conditions
- Liver Cirrhosis, Gastroesophageal Varices, Variceal Hemorrhage
- Trial name
- NCT04640350
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese PLA General Hospital
Liver Cirrhosis
Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells
Mesenchymal stem cells have the capability to differentiate into hepatocytes and will be useful for liver regeneration. Adipose tissue is relatively enriched with mesenchymal stem cells compared to bone marrow tissue.
- Trial name
- NCT00913289
- Testing
- adipose tissue derived stromal cells
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Kanazawa University
Liver Cirrhosis, Kidney Failure, Acute
Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction
In the planned randomized controlled prospective pilot study, we aim to evaluate ADVOS compared with conventional hemodialysis regarding the elimination of protein-bound toxins in patients with therapy-refractory hepatorenal…
- Conditions
- Liver Cirrhosis, Kidney Failure, Acute, Kidney Replacement, Multi Organ Failure
- Trial name
- ADVOMITTENT (NCT06129617)
- Testing
- Hemodialysis, ADVOS
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Medical Center Mainz
Primary Biliary Cholangitis
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
This study is a placebo-controlled, randomized, double-blind, multicenter, parallel-group comparison study in primary biliary cholangitis participants inadequately responding to ursodeoxycholic acid.
- Trial name
- NCT03092765
- Testing
- E6011
- Where
- 46 sites in Japan
- Volunteers
- 29 people
- Sponsor
- EA Pharma Co., Ltd.
Decompensated Cirrhosis, CMV Reactivation
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV)…
- Conditions
- Decompensated Cirrhosis, CMV Reactivation, Overt Hepatic Encephalopathy
- Trial name
- NCT06374511
- Testing
- Test for CMV reactivation
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Disease, Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Background: Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research.
- Trial name
- NCT03600714
- Testing
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Liver Lesions, Liver Cancer
Characterization of Focal Liver Lesions by Real-time Contrast-enhanced Ultrasound Imaging (CEUS)
The conventional sonography is frequently used to detect incidental focal liver lesions because of its availability, innocuity and low cost.
- Conditions
- Focal Liver Lesions, Liver Cancer, Liver Cirrhosis
- Trial name
- NCT00243633
- Testing
- Real-time contrast-enhanced ultrasound sonography
- Where
- 15 sites in France
- Volunteers
- 878 people
- Sponsor
- University Hospital, Tours
Primary Biliary Cholangitis
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients.
- Trial name
- NCT05751967
- Testing
- Fenofibrate Combined With Ursodeoxycholic Acid
- Where
- 7 sites in China
- Volunteers
- 150 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Liver Cirrhosis
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and…
- Trial name
- ZEAL (NCT05516498)
- Testing
- Part A: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin
- Where
- 50 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
NAFLD, NASH
LITMUS Imaging Study
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD).
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT05479721
- Where
- 18 sites in United States, Finland and 8 more
- Volunteers
- 450 people
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.